Showing results (1-10 of 36) with videos related to
Sort By:
Pageof 4
International Immunopharmacology|November 22, 2015
The therapeutic potential of microbial proteasome inhibitorsIsao Momose, Manabu KawadaYakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|February 3, 2022
[Boronic Acid as a Promising Class of Chemical Entity for Development of Clinical Medicine for Targeted Therapy of Cancer]Takumi Watanabe, Isao MomoseThe Journal of Antibiotics|February 16, 2017
Tyropeptins, proteasome inhibitors produced by Kitasatospora sp. MK993-dF2Isao Momose, Takumi WatanabeBioscience, Biotechnology, and Biochemistry|September 14, 2010
Increased ABCB1 expression in TP-110-resistant RPMI-8226 cellsMasatomi Iijima, Isao Momose, Daishiro IkedaYakugaku Zasshi : Journal of the Pharmaceutical Society of Japan|March 1, 2021
[Potential Anticancer Activity of Auranofin]Isao Momose, Takefumi Onodera, Manabu KawadaChemical & Pharmaceutical Bulletin|March 5, 2019
Potential Anticancer Activity of AuranofinTakefumi Onodera, Isao Momose, Manabu KawadaOncology Research|September 25, 2023
Deoxynortryptoquivaline: A unique antiprostate cancer agentYohko Yamazaki, Manabu Kawada, Isao MomoseAnticancer Research|May 6, 2009
TP-110, a new proteasome inhibitor, down-regulates IAPs in human multiple myeloma cellsMasatomi Iijima, Isao Momose, Daishiro IkedaBioscience, Biotechnology, and Biochemistry|November 27, 2002
Inhibition of proteasome activity by tyropeptin A in PC12 cellsIsao Momose, Ryuichi Sekizawa, Hironobu Iinuma, et al.Bioscience, Biotechnology, and Biochemistry|April 11, 2007
A new proteasome inhibitor, TP-110, induces apoptosis in human prostate cancer PC-3 cellsIsao Momose, Masatomi Iijima, Manabu Kawada, et al.Pageof 4